Mercury Laboratories Stock Screener | Share Price & Fundamental Analysis
MERCURYLAB
Pharmaceuticals
Screen Mercury Laboratories share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹825.00
▲
0.00 (0.00%)
Market Cap
₹98.30 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.76
EPS (TTM)
₹26.21
Dividend Yield
0.43%
Debt to Equity
0.11
52W High
₹920.40
52W Low
₹780.45
Operating Margin
11.00%
Profit Margin
6.33%
Revenue (TTM)
₹79.00
EBITDA
₹10.00
Net Income
₹5.00
Total Assets
₹74.00
Total Equity
₹54.00
Mercury Laboratories Share Price History - Stock Screener Chart
Screen MERCURYLAB historical share price movements with interactive charts. Analyze price trends and patterns.
Mercury Laboratories Company Profile - Fundamental Screener
Screen Mercury Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MERCURYLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE947G01011
Mercury Laboratories Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen MERCURYLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 74 | 68 | 64 | 62 | 65 | 56 | 57 | 52 | 51 | 47 |
| Current Assets | 40 | 40 | 40 | 35 | 38 | 32 | 32 | 30 | 32 | 28 |
| Fixed Assets | 25 | 24 | 24 | 26 | 26 | 24 | 24 | 21 | 18 | 19 |
| Liabilities | ||||||||||
| Total Liabilities | 74 | 68 | 64 | 62 | 65 | 56 | 57 | 52 | 51 | 47 |
| Current Liabilities | 6 | 5 | 4 | 6 | 10 | 9 | 11 | 12 | 10 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 54 | 51 | 46 | 40 | 37 | 32 | 29 | 26 | 25 | 22 |
| Share Capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves & Surplus | 52 | 50 | 44 | 39 | 36 | 31 | 28 | 25 | 23 | 21 |
Screen MERCURYLAB income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 79 | 76 | 77 | 77 | 59 | 70 | 58 | 57 | 52 | 48 | 48 | 42 |
| Expenses | 69 | 68 | 67 | 67 | 51 | 59 | 51 | 50 | 48 | 41 | 41 | 35 |
| EBITDA | 10 | 8 | 10 | 10 | 8 | 11 | 7 | 7 | 5 | 7 | 7 | 7 |
| Operating Profit % | 11.00% | 9.00% | 12.00% | 11.00% | 12.00% | 14.00% | 11.00% | 10.00% | 9.00% | 14.00% | 14.00% | 14.00% |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Interest | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 7 | 5 | 7 | 7 | 5 | 8 | 4 | 4 | 3 | 5 | 5 | 5 |
| Tax | 2 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 0 | 2 | 1 | 1 |
| Net Profit | 5 | 3 | 6 | 6 | 4 | 5 | 3 | 3 | 2 | 3 | 4 | 3 |
| EPS | 40.90 | 26.21 | 47.12 | 46.49 | 29.68 | 44.48 | 26.90 | 23.63 | 16.78 | 22.53 | 32.69 | 27.61 |
Mercury Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen MERCURYLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 4 | 8 | 3 | 5 | 8 | 6 | 5 | 5 | 2 | 0 |
| Investing Activities | -9 | -6 | -1 | -2 | -5 | -1 | -5 | -4 | -2 | 0 |
| Financing Activities | -1 | -1 | -1 | -1 | -1 | -3 | -3 | 1 | 0 | 1 |
| Net Cash Flow | -6 | 1 | 0 | 2 | 2 | 1 | -2 | 2 | 0 | 0 |
Screen MERCURYLAB shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.66% | 16.66% | 16.71% | 16.86% | 16.86% | 16.79% | 16.63% | 16.83% |
| Other Holding | 9.68% | 9.68% | 9.63% | 9.48% | 9.48% | 9.55% | 9.71% | 9.52% |
| Shareholder Count | 1,397 | 1,384 | 1,365 | 1,214 | 1,259 | 1,345 | 1,411 | 1,146 |
Mercury Laboratories Dividend Screener - Share Yield Analysis
Screen MERCURYLAB dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2025-March | ₹3.50 | 0.43% |
| 2024-March | ₹3.50 | 0.43% |
| 2023-March | ₹3.50 | 0.42% |
| 2022-March | ₹3.50 | 0.63% |
| 2021-March | ₹3.50 | 0.72% |
| 2020-March | ₹2.00 | 0.31% |
| 2019-March | ₹1.50 | 0.53% |
| 2018-March | ₹1.50 | 0.44% |
| 2017-March | ₹1.50 | 0.38% |
| 2016-March | ₹0.00 | 0.00% |
Mercury Laboratories Index Membership - Market Screener Classification
Screen MERCURYLAB by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Mercury Laboratories Market Events Screener - Corporate Actions
Screen MERCURYLAB market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 2.00 /share | -10.51% | ||
| Dividend | ₹ 3.50 /share | 24.21% | ||
| Dividend | ₹ 3.50 /share | 25.90% | ||
| Dividend | ₹ 3.50 /share | 19.51% | ||
| Annual General Meeting | NA | -1.49% | ||
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 2.38% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -6.45% |
| 2025-08-13 | 2025-08-13 | Annual General Meeting | NA | -4.77% |
| 2025-08-06 | 2025-08-06 | Dividend | ₹ 3.50 /share | -0.90% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -1.75% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -4.38% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.88% |
| 2021-02-22 | 2021-02-23 | Dividend | ₹ 1.50 /share | 4.00% |
Mercury Laboratories Competitors Screener - Peer Comparison
Screen MERCURYLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 421,539 | 40.16 | 54,729 | 9.71% | 10,980 | 46.18 |
| Divis Laboratories | 173,112 | 69.16 | 9,712 | 18.67% | 2,191 | 53.62 |
| Torrent Pharmaceuticals | 129,222 | 60.40 | 11,539 | 6.99% | 1,911 | 62.04 |
| Cipla | 121,624 | 22.30 | 28,410 | 7.12% | 5,291 | 44.91 |
| Dr Reddys Laboratories | 107,039 | 18.66 | 33,741 | 16.73% | 5,725 | 60.09 |
| Lupin | 96,138 | 22.21 | 22,910 | 13.74% | 3,306 | 60.88 |
| Zydus Life Science | 93,751 | 18.57 | 23,511 | 18.55% | 4,615 | 47.29 |
| Mankind Pharma | 92,528 | 51.90 | 12,744 | 20.90% | 2,007 | 53.62 |
| Aurobindo Pharma | 71,009 | 20.66 | 32,346 | 9.43% | 3,484 | 57.50 |
| Alkem Laboratories | 66,801 | 27.75 | 13,458 | 3.70% | 2,216 | 47.48 |
Mercury Laboratories Company Announcements - News Screener
Screen MERCURYLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-11 | Updates On New Small Volume Parenteral (Svps) Plant At Jarod | View |
| 2025-11-11 | Unaudited Financial Results For The Quarter And Half Year Ended On September 2025 | View |
| 2025-11-11 | Board Meeting Outcome for Outcome Of Board Meeting Held On November 11 2025 | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-05 | Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter And Half Year Ended On September 30 2025 Scheduled To Be Held On November 11 2025 | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-10-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-04 | Communication To Shareholders Regarding 100 Days Campaign - Saksham Niveshak | View |
| 2025-09-25 | Closure of Trading Window | View |
| 2025-08-14 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-13 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-08-13 | Unaudited Financial Results For The Quarter Ended On June 30 2025 | View |
| 2025-08-13 | Board Meeting Outcome for Outcome Of Board Meeting Held On August 13 2025 | View |
| 2025-08-05 | Board Meeting Intimation for To Consider And Approve Of Unaudited Financial Results For The Quarter Ended On June 30 2025 | View |
| 2025-07-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-07-17 | Notice Of 44Th AGM Of The Company To Be Held On August 13 2025 | View |
| 2025-07-17 | Reg. 34 (1) Annual Report. | View |